Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients

Starting soon · Phase 2

Conditions studied: Prurigo Nodularis (PN)

In brief

The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).

Key facts

Study ID

NCT07620561

Run by

University of Maryland, Baltimore

People needed

15

Starts

2026-06-01

Expected to finish

2028-03-01

Last updated by the study team

2026-06-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80
• Diagnosis of Prurigo Nodularis (PN) for at least 1 year
• Active PN with moderate-to-severe itch, several nodules, and presence of nodules in more than one part of the body
• Women of childbearing potential must agree to remain abstinent or use a highly effective contraceptive method during treatment and for at least 18 weeks after the last dose of study drug
• Male participants must agree to use an effective barrier contraceptive if sexually active with a woman of childbearing potential during treatment and for at least 18 weeks after the last dose of study drug

You may not qualify if…

• Prior participation in a lebrikizumab study
• History of anaphylaxis
• History of or active HIV
• Active hepatitis or known liver cirrhosis
• History of cancer in the past 5 years, except for fully treated early cervical cancer in situ or non-melanoma skin cancers (basal cell or squamous cell skin cancer) that have been successfully treated and resolved. This includes certain skin lymphomas such as mycosis fungoides.
• Uncontrolled chronic conditions that may require intermittent oral steroid use, such as severe uncontrolled asthma
• Current or recent parasitic infection
• Immunocompromised individuals
• Pregnant or breastfeeding women or those planning to become pregnant or breastfeed during the study period
• Use of other treatments for PN during the study, such as topical, systemic, or light-based treatments
• Current or recent treatment with biologic drugs
• Use of drugs that have an effect on the immune system during the study and within 4 weeks of starting the study
• Receipt of phototherapy or light-based therapy within 4 weeks before starting the study
• Regular use of tanning booths or parlors within 4 weeks before starting the study
• Receipt of a live vaccine within 12 weeks before starting the study or planned receipt during the study
• Recent use of an experimental drug
• Other protocol-defined Inclusion/Exclusion Criteria apply.

Where it is running

• UM Dermatology at UM Professional Building — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.